Form 4: Avanos Medical SVP Mojirade James Reports Acquisition and Disposal of Common Stock

Mojirade James, SVP and General Counsel of Avanos Medical, reported the acquisition of 30,695 shares of common stock and the disposal of 1,951 shares to cover tax obligations.

Summary

• On March 6, 2024, Mojirade James, SVP and General Counsel of Avanos Medical, acquired 30,695 shares of common stock at a price of $19.14 per share.
• These shares were awarded as time-based restricted share units (TRSUs) under the company's 2021 Long Term Incentive Plan.
• The TRSUs will vest in three equal installments on March 6, 2025, March 6, 2026, and March 6, 2027.
• On the same day, James disposed of 1,951 shares of common stock at $19 per share to satisfy tax withholding obligations related to the vesting of TRSUs awarded on March 6, 2023.
• Following these transactions, James directly owns 70,997 shares of Avanos Medical common stock.

Sentiment

Score: 6

Explanation: The document reflects standard insider trading activity related to executive compensation. It's neither overwhelmingly positive nor negative, but rather a routine disclosure.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document outlines the vesting schedule for the acquired TRSUs, indicating future dates when additional shares will vest.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency in insider trading activities.
• Companies like Medtronic, Boston Scientific, and Johnson & Johnson also have executives who regularly file Form 4s for similar transactions involving stock options and restricted stock units.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they reflect routine executive compensation and stock ownership changes.

Key Dates